Elizabeth Grubbs, MD is a Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center where she serves as Director of Faculty Academic Career Development for the institution. She is the Deputy Director of Education for the Division of Surgery as well as the Vice Chair of Education for the Department of Surgical Oncology.
Her clinical practice is dedicated to the treatment of benign and malignant endocrine disease. Clinical and research interests focus on the treatment of hereditary endocrine neoplasias and sporadic medullary thyroid cancer. She led the team that founded The MTC CoRe (Medullary Thyroid Cancer Collaborative Registry) Consortium and has current federal funding to evaluate natural history well as patient reported outcomes of this often chronic disease. She Is a member of the International Thyroid Oncology Group and a member of the adviosry board for ThyCa and AMENDSupport.

Dr. Mimi Hu is an oncologic endocrinologist and Professor and Deputy Chair of Clinical Affairs in the Department of Endocrine Neoplasia and Hormonal Disorders at The University of Texas MD Anderson Cancer Center. She is a member of the International Thyroid Oncology Group (ITOG), medical advisory panel for ThyCa, and steering committee member of the The MTC CoRe (Medullary Thyroid Cancer Collaborative Registry) Consortium. She has clinical focus and research interests in the treatment of patients with medullary and differentiated thyroid cancer and hereditary endocrine syndromes. She has served as the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid carcinoma. She has published articles and book chapters evaluating the management of medullary thyroid carcinoma and multiple endocrine neoplasia.

Anne Brinkman, APRN is a Nurse Practitioner in the Department of Endocrine Neoplasia and Hormone Disorders at the University of Texas MD Anderson Cancer Center where she serves as Supervisor of the Outpatient Advanced Practice Provider team. Her clinical practice is dedicated to patient education and the evaluation and treatment of a range benign and malignant endocrine tumors.

Maria E. Cabanillas, M.D. is an Oncologic Endocrinologist at the University of Texas MD Anderson Cancer Center in Houston, Texas where she is a Professor and the Faculty Director of Clinical Research in the Department of Endocrine Neoplasia and Hormonal Disorders.

As a clinician and clinical researcher, she focuses her practice on both early and advanced thyroid cancers, including medullary, differentiated, and anaplastic thyroid cancers. Her research focus is in advanced and aggressive thyroid cancer, with an emphasis that includes molecular targeted therapies and immunotherapy. Dr. Cabanillas serves as the principal investigator on several clinical trials for the treatment of advanced thyroid cancer. She has been a member of the International Thyroid Oncology Group (ITOG) since 2012 .

Julie Ann Sosa, MD MA FACS is the Leon Goldman MD Distinguished Professor of Surgery and Chair of the Department of Surgery at the University of California San Francisco (UCSF), where she is also a Professor in the Department of Medicine and affiliated faculty for the Philip R. Lee Institute for Health Policy Studies. Her clinical interest is in endocrine surgery, with a focus in thyroid cancer. Dr. Sosa coleads theMTC CoRe (Medullary Thyroid Cancer Collaborative Registry) Consortium with Dr. Grubbs. She is an NIH- and FDA-funded investigator whose work is focused on outcomes research, health care delivery, hyperparathyroidism, and thyroid cancer, with a focus on clinical trials. Dr Sosa served as president from 2022-2023 for the American Thyroid Association (ATA) and serves on the Board of Directors/Executive Council of the ATA and International Thyroid Oncology Group, as well as practice guidelines committees for the ATA, NCCN, and the American Association of Endocrine Surgeons; for the ATA, she is chairing the committee responsible for writing the next iteration of differentiated thyroid cancer guidelines.

Steven G. Waguespack, MD is a Professor in the Department of Endocrine Neoplasia and Hormonal Disorders (with a joint appointment in the Department of Pediatrics-Patient Care) at the University of Texas MD Anderson Cancer Center in Houston, TX, USA. He is uniquely trained in both adult and pediatric endocrinology and maintains board certification in both subspecialties. Although his scope of practice is broad, Dr. Waguespack’s major clinical and research interests are thyroid cancer, hereditary endocrine tumor syndromes, and pituitary tumors. Dr. Waguespack served as a member of the ATA task force that revised the medullary thyroid cancer guidelines in 2015, was a co-chair of the inaugural 2015 ATA guidelines for pediatric thyroid nodules and differentiated thyroid cancer. Considered to be an expert in thyroid cancer and other endocrine tumors, Dr. Waguespack is privileged to be able to care for patients with these diseases across the age continuum.

Dr. Mark Zafereo is a Professor of Head and Neck Surgery at MD Anderson Cancer Center in Houston, Texas. He is Section Chief of Head and Neck Endocrine Surgery and Associate Medical Director of the Head & Neck Center at MD Anderson Cancer Center. Dr. Zafereo holds national committee appointments for the American Head and Neck Society, American Academy of Otolaryngology-Head and Neck Surgery, American Thyroid Association, International Thyroid Oncology Group, and American College of Surgeons. He leads several national multicenter clinical trials on neoadjuvant therapy followed by surgery for anaplastic and medullary thyroid cancers. His clinical practice focuses on patients afflicted with thyroid cancer and parathyroid neoplasms. He serves on the steering committee member of the The MTC CoRe (Medullary Thyroid Cancer Collaborative Registry) Consortium.